Live Feeds
● TRACKER Updated 33d ago · 20 sources tracked

AbbVie's Cerevel buyout delivers as FDA gives go-ahead to 1st-in-class Juvmo in Parkinson's disease

The US FDA approved Juvmo, a once-daily oral medication for adults with Parkinson's disease. As the only selective D1/D5 receptor agonist in its class, the drug demonstrated longer symptom control and improved motor symptoms during the Phase 3 TEMPO program. This approval marks the first product resulting from AbbVie's 8.7 billion dollar purchase of Cerevel two years ago. AbbVie management anticipates a slow initial entry into the market.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (20)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ The US FDA approved Juvmo for adults with Parkinson's disease.
  • ✓ Juvmo is a once-daily oral selective D1/D5 receptor agonist.
  • ✓ The Phase 3 TEMPO program showed significant improvements in motor symptoms and longer periods of symptom control.
  • ✓ AbbVie acquired Cerevel for 8.7 billion dollars two years ago.
🛡️ Source Corroboration: 20 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

No new developments regarding Juvmo or the Cerevel acquisition have occurred since the initial FDA approval report.

Live updates

  1. FDA Approves Juvmo for Parkinson's Disease

    The US FDA approved Juvmo, a once-daily oral medication for adults with Parkinson's disease. As the only selective D1/D5 receptor agonist in its class, the drug demonstrated longer symptom control and improved motor symptoms during the Phase 3 TEMPO program. This approval marks the first product resulting from AbbVie's 8.7 billion dollar purchase of Cerevel two years ago. AbbVie management anticipates a slow initial entry into the market.

    Why it matters

    The acquisition of Cerevel was a strategic move by AbbVie to expand its neurological portfolio. Juvmo provides a new mechanism of action for treating motor symptoms in Parkinson's patients.

    What is confirmed

    • The US FDA approved Juvmo for adults with Parkinson's disease.
    • Juvmo is a once-daily oral selective D1/D5 receptor agonist.
    • The Phase 3 TEMPO program showed significant improvements in motor symptoms and longer periods of symptom control.
    • AbbVie acquired Cerevel for 8.7 billion dollars two years ago.

    What to watch next

    • Market adoption rates for Juvmo
    • Post-market safety data from the general population
    Sources used for this update (2)
    1. careers.abbvie.com — Difference makers wanted | AbbVie
    2. agents.stackoverflow.com — Home - Stack Overflow for Agents
    confidence 100%
  2. FDA Approves AbbVie Parkinson's Drug Juvmo

    The US FDA approved Juvmo (tavapadon), a once-daily oral medication for adults with Parkinson's disease. Juvmo is the first and only selective D1/D5 receptor agonist in its class. The drug showed significant improvements in motor symptoms and longer periods of symptom control during the Phase 3 TEMPO program. This approval represents the first product delivered from AbbVie's 8.7 billion dollar acquisition of Cerevel, which took place two years ago. Despite the approval, AbbVie management expects a slow start for the medication's market entry.

    Why it matters

    The approval validates a multi-billion dollar investment in Cerevel to expand AbbVie's neurology portfolio. As a first-in-class treatment, Juvmo introduces a new mechanism for managing Parkinson's motor symptoms. The drug's success is tied to its ability to provide prolonged symptom control compared to existing therapies.

    What is confirmed

    • The FDA approved Juvmo (tavapadon) for the treatment of adults with Parkinson's disease.
    • Juvmo is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson.
    • AbbVie acquired Cerevel for 8.7 billion dollars two years ago.
    • Juvmo is administered as a once-daily oral treatment.
    • The Phase 3 TEMPO program demonstrated that Juvmo elicited significant improvements in motor symptoms and prolonged periods with good symptom control.

    Still unconfirmed

    • A Cleveland Clinic doctor led the development of this breakthrough treatment.
    • AbbVie management expects a slow start for Juvmo.

    What to watch next

    • Market adoption rates and initial sales figures for Juvmo
    • Clinical data on long-term efficacy beyond the TEMPO program
    Sources used for this update (24)
    1. fiercepharma.com — AbbVie's Cerevel buyout delivers as FDA gives go-ahead to 1st-in-class Juvmo in Parkinson's disease
    2. Reuters — US FDA approves AbbVie's drug for Parkinson's disease
    3. BioSpace — AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover
    4. MedPage Today — Parkinson's Disease Gets New Treatment Approved
    5. Yahoo Finance — AbbVie Won FDA Approval for Parkinson’s Pill Juvmo. Here’s Why Management Already Expects a Slow Start
    6. FOX 8 News — FDA approves ‘breakthrough’ Parkinson’s treatment led by Cleveland Clinic doctor
    7. Crain's Chicago Business — AbbVie’s $8.7B Cerevel deal pays off with Parkinson’s drug approved for U.S. patients
    8. Ynetnews — New Parkinson’s drug approved in the US: What does it do differently?
    9. Medscape — FDA Approves First-In-Class Med for Parkinson's Disease
    10. WGN-TV — FDA approves Juvmo, a first-of-its-kind medication for Parkinson’s disease
    11. www.biospace.com — AbbVie wins FDA approval for Parkinson’s drug from $8.7B ...
    12. news.abbvie.com — U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's ...
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community